FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and concerns using a derivative of Alloferon-1 Phe(p-NH2)-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly as an agent possessing high immunomodulatory and antiviral activity. The group of inventions also refers to an immunomodulatory and antiviral composition containing peptide Phe(p-NH2)-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly or its pharmaceutically acceptable salts in a combination with standard additives.
EFFECT: group of inventions provides stimulating induction of interleukin-18, interferon gamma and inhibition of influenza A and B viruses.
2 cl, 4 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BIOLOGICALLY ACTIVE PEPTIDES | 2013 |
|
RU2575069C2 |
| BIOLOGICALLY ACTIVE PEPTIDE COMPLEXES | 2011 |
|
RU2470031C2 |
| ANTI-TUMOR AND ANTIVIRAL PEPTIDES | 2004 |
|
RU2267496C2 |
| ALLOPHERONES AS IMMUNOMODULATING PEPTIDES | 1999 |
|
RU2172322C1 |
| AGENT POSSESSING BIOCIDAL ACTION | 2017 |
|
RU2673807C2 |
| AGENT FOR EXTERNAL APPLICATION, POSSESSING ANTIVIRAL ACTIVITY | 2006 |
|
RU2338553C2 |
| RABIES VACCINE | 2014 |
|
RU2712743C2 |
| RECOMBINANT PLASMID DNA ENCODING CHIMERIC INTERFERON ALPHA2b, RECOMBINANT STRAIN OF YEAST P. PASTORIS X33 - PRODUCER OF CHIMERIC INTERFERON ALPHA2b, AND METHOD FOR PRODUCING THIS PROTEIN | 2020 |
|
RU2764787C1 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
